Year None2022202120202019201820172016201520142013 Jan 20 View HTML version View PDF Version Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search Jan 19 View HTML version View PDF Version FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC Jan 19 View HTML version View PDF Version Second Positive Phase 3 Dupixent® (dupilumab) Trial Confirms Significant Improvements for Patients with Prurigo Nodularis Jan 13 View HTML version View PDF Version Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on Jan 7 View HTML version View PDF Version Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4